Implant Sciences Exhibits Its Brachytherapy Seed At Astro 2000 Conference and Technical Exhibit.Business Editors BOSTON--(BUSINESS WIRE)--Oct. 24, 2000 An FDA-cleared, next generation radioactive brachytherapy seed for the treatment of early stage prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. is being showcased by Implant Sciences Corporation (AMEX AMEX See: American Stock Exchange : IMX IMX In My eXperience IMX Interactive Music Exchange (TV show) IMX Integrated Multimedia Exchange IMX Industrywide Mortgage Exchange IMX Intermodal Marketing Extension IMX Inverse Multiplexor , IMX.WS; BSE See Bombay Stock Exchange. BSE See Boston Stock Exchange (BSE). : IMX) at the 42nd annual conference and technical exhibit of the American Society for Therapeutic Radiology and Oncology, Inc. (ASTRO) at the John B. Hynes Veterans Memorial Convention Center in Boston from Oct. 22 to Oct. 25. Implant Sciences, based in Wakefield, MA, develops products for the radiation oncology radiation oncology n. The branch of radiology that deals with the use of ionizing radiation to treat cancers. radiation oncology , interventional cardiology interventional cardiology Cardiology The subspecialty of cardiology dedicated to the diagnosis, medical and mechanical therapy, pre- and post-procedure management of adult patients with acute and chronic forms of cardiovascular disease amenable to catheter-based and orthopedic markets. ASTRO is accredited accredited recognition by an appropriate authority that the performance of a particular institution has satisfied a prestated set of criteria. accredited herds cattle herds which have achieved a low level of reactors to, e.g. by the Accreditation Council for Continuing Medical Education The Accrediting Council for Continuing Medical Education (ACCME) is the overseeing body for continuing medical education (CME) in the United States. The ACCME sets the standards for the accreditation of all providers of CME activities. to provide continuing medical education continuing medical education See CME. for physicians. Radiation oncologists, radiation oncology residents, radiation biologists, radiation physicists and other health professionals involved in the field of radiation oncology who visit booth #901 will be introduced to the benefits of the company's I-Plant(TM) Iodine-125 radioactive seeds. The company is also running three buses a day to transport groups of radiation oncologists and medical physicists to tour its newly completed automated production line, which manufactures the prostate seed. Participants will see the automation and testing applied to 100 percent of the seeds manufactured. The seeds are small encapsulated radiation sources approximately half the size of a grain of rice, which are placed directly into the prostate in a procedure known as brachytherapy. On Aug. 18, 2000 Vanderbilt University Medical Center The Vanderbilt University Medical Center (VUMC) is a collection of several hospitals and clinics associated with Vanderbilt University in Nashville, Tennessee. It comprises the following units:[2]
The permanent implant of radioactive seeds for the primary treatment of prostate cancer is a proven technique that is rapidly gaining acceptance. The procedure involves placement of approximately 100 radioactive seeds directly into the prostate, and is usually performed on an outpatient basis with rapid recovery. Implant Sciences markets its I-Plant(TM) Iodine-125 radioactive seed through an exclusive U.S. distribution agreement with MED-TEC, Inc., a highly regarded supplier of medical products to the urology/radiation oncology community. The I-Plant(TM) seed is produced at Implant Sciences' 39,300 square-foot facility, located in Wakefield, MA, where the seed cores are ion implanted with non-radioactive Xenon-124 gas, which can be safely inventoried in large quantities. As needed as needed prn. See prn order. , the seed cores are then placed in a nuclear reactor to transmute the Xenon-124 into Iodine-125. The non-radioactive dry fabrication process enables a just in time manufacturing for distribution opportunities and economies that, the company believes, conventional manufacturing does not offer. Implant Sciences Corporation develops products for the medical device industry using ion implantation and thin film coatings of radioactive and non-radioactive materials. The company has received Food and Drug Administration 510(k) clearance to market its I-Plant(TM) Iodine-125 radioactive seed for the treatment of prostate cancer and has recently partnered with MED-TEC, Inc. for its exclusive U.S. distribution. The company also has under development interventional cardiology devices, temporary coronary brachytherapy systems and radioactive coronary stents, for the prevention of restenosis (reclosure of the artery) after balloon angioplasty. In addition, the company modifies the surface characteristics of orthopedic joint implants to reduce polyethylene wear, thereby increasing the life of the implant. For more information, please visit our web site at www.implantsciences.com The company believes that this interview contains forward-looking statements that are subject to risks and uncertainties. These forward-looking statements include past and expected results of the clinical trials and marketing activities. Such statements are based on management's current expectations and are subject to a number of facts that could cause actual results to differ materially from the forward-looking statements. Consult the Company's SEC filings. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion